CO2021004612A2 - Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento - Google Patents
Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamentoInfo
- Publication number
- CO2021004612A2 CO2021004612A2 CONC2021/0004612A CO2021004612A CO2021004612A2 CO 2021004612 A2 CO2021004612 A2 CO 2021004612A2 CO 2021004612 A CO2021004612 A CO 2021004612A CO 2021004612 A2 CO2021004612 A2 CO 2021004612A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrazin
- ylmethyl
- medicine
- morpholine derivatives
- nr2b
- Prior art date
Links
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 2
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a 4 pirazin 2 ilmetil-morfolinas novedosas de la Fórmula general A A, procesos para su preparación, composiciones farmacéuticas que las contienen y su uso en tratamientos, particularmente, en el tratamiento o la prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200943 | 2018-10-17 | ||
| PCT/EP2019/078027 WO2020079039A1 (en) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021004612A2 true CO2021004612A2 (es) | 2021-04-30 |
Family
ID=63878518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0004612A CO2021004612A2 (es) | 2018-10-17 | 2021-04-13 | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11166958B2 (es) |
| EP (1) | EP3867244B1 (es) |
| JP (1) | JP7093468B2 (es) |
| KR (1) | KR20210079325A (es) |
| CN (1) | CN112888685B (es) |
| AR (1) | AR116711A1 (es) |
| AU (1) | AU2019362330B2 (es) |
| BR (1) | BR112021004993A2 (es) |
| CA (1) | CA3113308A1 (es) |
| CL (1) | CL2021000858A1 (es) |
| CO (1) | CO2021004612A2 (es) |
| CR (1) | CR20210184A (es) |
| DK (1) | DK3867244T3 (es) |
| DO (1) | DOP2021000069A (es) |
| EA (1) | EA202191014A1 (es) |
| EC (1) | ECSP21027009A (es) |
| ES (1) | ES2940184T3 (es) |
| FI (1) | FI3867244T3 (es) |
| HR (1) | HRP20230249T1 (es) |
| HU (1) | HUE061891T2 (es) |
| IL (1) | IL282142B2 (es) |
| JO (1) | JOP20210075A1 (es) |
| LT (1) | LT3867244T (es) |
| MA (1) | MA53898B1 (es) |
| MX (1) | MX2021004418A (es) |
| PE (1) | PE20211278A1 (es) |
| PH (1) | PH12021550834A1 (es) |
| PL (1) | PL3867244T3 (es) |
| PT (1) | PT3867244T (es) |
| RS (1) | RS63988B1 (es) |
| SA (1) | SA521421756B1 (es) |
| SG (1) | SG11202103806VA (es) |
| SI (1) | SI3867244T1 (es) |
| TW (1) | TWI828779B (es) |
| WO (1) | WO2020079039A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980401A1 (en) * | 2019-06-04 | 2022-04-13 | Boehringer Ingelheim International GmbH | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| AU2002338334B8 (en) | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| MXPA04000737A (es) * | 2001-07-24 | 2004-07-08 | Richter Gedeon Vegyeszet | Derivados de piperidina como antagonistas receptores de nmda. |
| US7855201B2 (en) * | 2005-12-06 | 2010-12-21 | Merck Sharp & Dohme. Corp. | Morpholine carboxamide prokineticin receptor antagonists |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| KR101684816B1 (ko) | 2012-10-18 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 활성의 조절제로서 에틴일 유도체 |
| US9676757B2 (en) | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| WO2017066368A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
-
2019
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/en active Application Filing
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/en active Active
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko unknown
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/en active Pending
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20040257A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CO2020006648A2 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento | |
| BR112017009850A2 (pt) | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| UY36273A (es) | Composicion para el tratamiento de neuropatías y del dolor neuropático | |
| BR112017002911A2 (pt) | composição para prevenção ou tratamento de obesidade contendo ácido alfa-lipóico e n-acetilcisteína como ingredientes ativos | |
| ECSP19024033A (es) | Composiciones de tesofensina | |
| BR112019021330A2 (pt) | Métodos e compostos terapêuticos. |